Phagelux announces presentation and infrastructure updates

SHANGHAI, MONTREAL and SALT LAKE CITY, Jan. 7, 2016 /CNW/ - Phagelux, Inc., which utilizes bacteriophages, lysins and related technologies to create solutions for bacterial problems including adjuncts and alternatives to antibiotics, announced today that Mark Engel, Chief Executive Offer, will present a corporate overview at the 8^th Annual Biotech Showcase Conference in San Francisco on Wednesday January 13, 2016 at 2:45 pm PST.  Mr. Engel will outline the lead programs of the company.

Phagelux also announced today that it continues to improve the infrastructure necessary to support the scientific and sales endeavors of the company.  According to Mr. Engel, recent improvements include the opening of a new pilot manufacturing facility in Suzhou China in January 2016, the upcoming expansion of the main China lab in Nanjing China, and the scheduled opening of a new 15,000 SF dedicated lysin development facility in Wuhan China in February 2016.   

About Phagelux, Inc.

Phagelux is headquartered in Shanghai with laboratories in China and North America and manufacturing facilities in the United States and China. Phagelux has both HumanHealth and AgriHealth divisions.

SOURCE Phagelux, Inc.

Media Contact: Aileen Shen, Assistant to the Chairman, [email protected], [phone]